Sistemic Ltd, a Glasgow, Scotland, UK, biotech company, closed an undisclosed Series A funding round.
ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund led the round.
The company will use the capital to further develop its proprietary SistemRNA compound-centric drug discovery technology, which enables accurate prediction of potential drug indications, interactions and side effects.
According to CEO Chris Hillier, the new funding will also enable Sistemic to expand its knowledge base in cardiac and anti-inflammatory indications, and to accelerate commercial operations.
FinSMEs
04/02/2010